Author:
Bergman Andries M.,Pinedo Herbert M.,Veerman Gijsbert,Kuiper Catharina M.,Peters Godefridus J.
Reference17 articles.
1. R.P Abratt, W. Rezwoda, G. Falkson, L. Goedhals, D. Hacking, Efficacy and safety profile of gemcitabine in non-small cell lung cancer. Phase II study, J. Clin. Oncol., 12: 1535–1540 (1994).
2. B. Lund, O.P. Hansen, K. Theilade, M. Hansen, J.P. Neijt, Phase II study of gemcitabine (2′,2′-difluorode-oxycytidine) in previously treated ovarian cancer patients, J. Natl. Cancer Inst., 86: 1530–1533 (1994).
3. C.J.A. van Moorsel, G. Veerman, A.M. Bergman, A. Guechev, J.B. Vermorken, P.E. Postumus, G.J. Peters, Combination chemotherapy studies with gemcitabine, Sem. Oncol., in press.
4. V.W.T. Ruiz van Haperen, G. Veerman, J.B. Vermorken, G.J. Peters, 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines, Biochem. Pharmacol., 46: 762–766 (1993).
5. P. Huang, S. Chubb, L.W. Hertel, G.B. Grindey, W. Plunkett, Action of 2′,2′-difluorodeoxycytidine on DNA synthesis, Cancer Res., 51: 6110–6117 (1991).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献